Olmesartan/Amlodipine/Hct Eg

Olmesartan medoxil, the active ingredient in Olmesartan/Amlodipine/Hct Eg, is an angiotensin II receptor blocker presented as a combination tablet for oral use. It treats hypertension, often in combination with other antihypertensive agents, and may be prescribed for patients who require multiple mechanisms of blood pressure control.

GNH USA supplies Olmesartan/Amlodipine/Hct Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan/Amlodipine/Hct Eg is used in the management of cardiovascular conditions that involve elevated blood pressure. - Hypertension: helps lower systolic and diastolic blood pressure to reduce cardiovascular risk. - Hypertensive heart disease: assists in decreasing cardiac workload and preventing disease progression. - Chronic kidney disease with hypertension: aids in slowing renal function decline associated with high blood pressure.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Dizziness or light‑headedness - Headache - Peripheral edema - Flushing - Fatigue - Increased urination

Serious or Rare Side Effects: - Severe hypotension - Electrolyte disturbances (e.g., low potassium) - Acute kidney injury - Angio‑edema - Liver enzyme elevation - Blood cell abnormalities

When prescribing this combination, clinicians should consider several safety aspects. - Renal function: assess baseline creatinine and monitor periodically. - Electrolytes: check potassium and sodium levels, especially with diuretic component. - Pregnancy: avoid use; teratogenic risk is present. - Elderly patients: start at lower dose and monitor for orthostatic hypotension. - Drug‑induced liver disease: use cautiously in patients with hepatic impairment. Store at ambient temperature: keep in the original container, protect from moisture and light.

Olmesartan/Amlodipine/Hct Eg can interact with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - Aliskiren: may cause excessive potassium loss and renal dysfunction when combined with an ARB. - Potassium‑saving diuretics or supplements: increase risk of hyperkalaemia. - Strong CYP3A4 inhibitors (e.g., itraconazole): raise amlodipine levels, heightening hypotension risk.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive effect and affect renal function. - Lithium: concurrent use can raise lithium concentrations. - Other antihypertensives: additive blood‑pressure lowering may require dose adjustment.